The use of AI in drug discovery has yielded interesting candidates and new ways of "in silico" testing. Join industry expert Brandon Allgood, Chief AI Officer at Valo Health, in a discussion of how innovative biotechs are using AI as a competitive advantage in drug discovery and clinical trials.

Access to quality data is one of the most important accelerators of growth for emerging biotechs. The resulting analysis and insights are enabling a golden age for research and therapy development as modern drug development teams are leveraging technology to unlock scientific data in new ways. Join this discussion to learn about digital workflow automation and the development of NIMBEye, Nimbus’ cloud computing environment that has accelerated the deployment of CRO data from days to minutes.

Scientists can now generate more data in a single day than they could in the preceding decade. Today, translating this deluge of data into actionable insights has become the rate-limiting step to scientific discovery. Researchers struggle to access the computational infrastructure, niche informatics tooling, and data science expertise required to realize the full potential of their experiments. Dr. Mark Kalinich discusses these challenges, reviews the available solutions, and shares how a fully-integrated Bio-IT platform can accelerate scientific discovery and the development of targeted therapeutics and diagnostics.

The traditionally risk-averse clinical trial industry has started to explore more advanced technologies in order to evolve how trials are run - exploring topics like real-world data capture, decentralized trial execution, faster patient enrollment, and better trial data analytics. In this session, learn how these new technologies are enabling smarter trial design, intended to generate better insights and accelerate time to patient.